Thought Leader Utilization: Refining Strategies and Tactics for Optimal KOL Engagement

  • ID: 4382196
  • Report
  • 106 pages
  • Arx Research
1 of 3
This study investigates how life science organizations interact with thought leaders throughout the phases of product development. Details reveal how pharmaceutical organizations engage with thought leaders, which types of thought leaders are targeted during the various phases of a product development, which levels of influence are most pursued and what sort of activities are conducted during these exchanges. Results are presented from a global perspective and by regional segments for US, Europe and others (Asia and Latin America combined).

We conducted the following study to identify best practices, gather insights and develop benchmarks for optimal thought leader engagement. The findings presented in this study result from the input of 47 respondents from 34 life sciences organizations from 15 countries across Asia, Europe, Latin and North America.

Thought leaders are critical to the life science environment and to ensure pharmaceutical organizations make physicians and patients aware of products’ scientific uses, outcomes and benefits.

Medical affairs executives and medical field teams need to work with a pool of thought leaders that has shrunk over the past few years due to the implementation of reporting regulations. It then becomes imperative that medical affairs professionals make the best out of each thought leader relationship they develop.

According to this research, the establishment of relationships between life science organizations and thought leaders may start very early in a product’s development. These relationships often are maintained many years after a product has been marketed.

While many organizations strategize on which type of thought leader to use during each phase of development, and what type of activity should be involved, many still don’t apply any specific tactics, preferring an ad-hoc approach to interacting with thought leaders.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Study Highlights

2. Research Methodology

3. Respondents’ Profiles
Working Environments

Profiled Companies

4. Thought Leaders’ Point of Contact
Medical Science Liaisons Involvements in Product Lifecycle

Functions and Roles Involved During Engagements

Factors Influencing KOL Relationships Development

5. Thought Leader Engagement Approaches, Timelines and Categories
Engagement Approaches

Timeline of Initial Thought Leader Engagement

Targeted Thought Leader Categories

6. Thought Leader Utilization during Pre-Clinical Phase
Thought Leader Targets

Targeted Levels of Thought Leader Influence

Thought Leader Activities

7. Thought Leader Utilization during Phase 1
Thought Leader Targets

Targeted Levels of Thought Leader Influence

Thought Leader Activities

8. Thought Leader Utilization during Phase 2
Thought Leader Targets

Targeted Levels of Thought Leader Influence

Thought Leader Activities

9. Thought Leader Utilization during Phase 3
Thought Leader Targets

Targeted Levels of Thought Leader Influence

Thought Leader Activities

10. Thought Leader Utilization during Launch
Thought Leader Targets

Targeted Levels of Thought Leader Influence

Thought Leader Activities

11. Thought Leader Utilization during Post Launch
Thought Leader Targets

Targeted Levels of Thought Leader Influence

Thought Leader Activities

12. Thought Leader Utilization for Organizations without Specific “by-phase”
Engagement Strategy

Thought Leader Targets

Targeted Levels of Thought Leader Influence

13. Access to Thought Leaders
Degree of Difficulty

14. In Summary
Aggregate Study Results

Thought Leader Engagement Strategy Framework ModeStudy Highlights
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll